Your browser is no longer supported. Please, upgrade your browser.
Settings
GSK GlaxoSmithKline plc daily Stock Chart
GSK [NYSE]
GlaxoSmithKline plc
Index- P/E265.41 EPS (ttm)0.15 Insider Own0.20% Shs Outstand2.43B Perf Week-0.77%
Market Cap94.26B Forward P/E14.05 EPS next Y2.76 Insider Trans0.00% Shs Float2.43B Perf Month0.54%
Income366.00M PEG22.68 EPS next Q0.63 Inst Own8.90% Short Float0.23% Perf Quarter-6.11%
Sales32.33B P/S2.92 EPS this Y204.10% Inst Trans0.04% Short Ratio1.36 Perf Half Y-10.09%
Book/sh0.07 P/B553.57 EPS next Y7.07% ROA0.50% Target Price48.25 Perf Year6.42%
Cash/sh2.35 P/C16.49 EPS next 5Y11.70% ROE13.90% 52W Range35.49 - 44.54 Perf YTD0.62%
Dividend1.85 P/FCF- EPS past 5Y40.20% ROI41.40% 52W High-13.01% Beta0.93
Dividend %4.77% Quick Ratio0.70 Sales past 5Y-3.40% Gross Margin67.00% 52W Low9.17% ATR0.41
Employees101192 Current Ratio1.00 Sales Q/Q23.10% Oper. Margin6.60% RSI (14)49.20 Volatility0.99% 0.88%
OptionableYes Debt/Eq140.32 EPS Q/Q49.60% Profit Margin1.10% Rel Volume0.95 Prev Close38.89
ShortableYes LT Debt/Eq111.62 EarningsJan 25 Payout- Avg Volume4.06M Price38.75
Recom2.00 SMA20-0.13% SMA500.56% SMA200-5.65% Volume3,867,275 Change-0.36%
Oct-20-16Initiated Investec Buy
Sep-23-16Initiated Piper Jaffray Overweight
Jul-14-16Upgrade Jefferies Hold → Buy
Mar-30-16Upgrade Citigroup Neutral → Buy
Feb-26-16Initiated Cantor Fitzgerald Hold
Dec-09-15Upgrade BofA/Merrill Neutral → Buy
Dec-07-15Reiterated Argus Buy $52 → $48
Oct-20-15Upgrade Credit Suisse Underperform → Neutral
Sep-15-15Upgrade Exane BNP Paribas Underperform → Neutral
Sep-08-15Upgrade BofA/Merrill Underperform → Neutral
Jun-26-15Upgrade Liberum Sell → Hold
Jun-04-15Downgrade Morgan Stanley Overweight → Equal-Weight
May-20-15Resumed Citigroup Neutral
Apr-15-15Initiated Societe Generale Sell
Feb-19-15Reiterated Argus Buy $55 → $52
Aug-08-14Reiterated Argus Buy $65 → $55
Apr-23-14Upgrade Argus Hold → Buy
May-28-13Upgrade Deutsche Bank Hold → Buy
Jan-11-11Upgrade Jefferies Hold → Buy
Jun-02-10Upgrade Jefferies Hold → Buy
Jan-19-17 01:15PM  Why is Pharma Struggling to Grow EPS? at Investopedia
06:55AM  Glaxo CEO Seeks Greater Transparency on Drug Pricing
05:13AM  GSK grabs Astra executive to replace pharma head
02:15AM  GSK grabs Astra executive to replace exiting pharma head
Jan-18-17 05:00PM  Ebola, Zika Push Drugmakers Into Effort to Avert Pandemics at Bloomberg
Jan-17-17 01:38PM  In This Case Silence Could be Golden at Investopedia
Jan-16-17 10:37AM  How Is Novartiss Revenue Trending?
09:07AM  How Did Novartis Perform in 3Q16?
08:38AM  5 Trump-Proof Pharma Dividends Up To 5.3% at Forbes
07:37AM  How Does Novartiss Valuation Compare to Peers?
Jan-14-17 03:57PM  Is GlaxoSmithKline's Stock a Bargain After Dropping 4.8% in 2016? at Motley Fool
Jan-13-17 09:55AM  4 Signs Glaxo's Turnaround Is Taking Hold at Motley Fool
Jan-11-17 07:29PM  Full Show: What'd You Miss? (01/11) at Bloomberg
04:53PM  GlaxoSmithKline's Redfern on Drug Pricing
04:53PM  GlaxoSmithKline's Redfern on Drug Pricing at Bloomberg
Jan-09-17 08:01AM  Adaptimmune confirms GSK Nomination of Second Adaptimmune Target under Strategic Multi-Target Collaboration GlobeNewswire
Jan-06-17 11:00AM  NeRRe, A GlaxoSmithKline PLC (ADR) (GSK) Spinout Raises £23 Million For NK Antagonists at Insider Monkey
08:24AM  The Best Thing About Glaxo's Next Vaccine (Hint: It's Not the Billion-Dollar Sales Estimate) at Motley Fool
08:17AM  Bristol-Myers, J&J Ink Immunotherapy Research Collaboration
Jan-05-17 04:41PM  Mylan, Novartis, Hikma Take On GSK In Generic Asthma Battle
Jan-04-17 06:25AM  4 Reasons Why Pfizer (PFE) Could be a Great Pick in 2017
Jan-03-17 11:09AM  GlaxoSmithKline Plc : GSK-US: Dividend Analysis : November 04th, 2016 (record date) : By the numbers : January 3, 2017
Jan-02-17 09:06AM  GlaxoSmithKlines Vaccines Business
Dec-30-16 01:19PM  10 Famous Corporate Whistleblowers in Publicly-Traded Companies at Insider Monkey
12:05PM  Top Ranked Income Stocks to Buy for December 30th
10:36AM  A Look at GlaxoSmithKlines HIV Business
09:07AM  How GlaxoSmithKlines Pharmaceuticals Segment Has Performed
07:38AM  Exploring GlaxoSmithKlines Business Segments
06:37AM  Merck (MRK) Does Well in 2016: Reasons for Outperformance
Dec-29-16 05:05PM  GlaxoSmithKlines Revenue Trend
03:27PM  How GlaxoSmithKlines Valuation Compares to Its Peers
07:36AM  United Therapeutics Robust Research Pipeline
01:00AM  No Quick Wins for GSK at Bloomberg
Dec-28-16 05:38PM  2 Top High-Yield Dividend Stocks to Buy Now at Motley Fool
09:06AM  VRXs Gastrointestinal Segment Saw Robust Revenue Growth in 2016
Dec-27-16 01:03PM  ETFs with exposure to GlaxoSmithKline Plc : December 27, 2016
Dec-26-16 08:57AM  GlaxoSmithKline Plc :GSK-US: Earnings Analysis: Q3, 2016 By the Numbers : December 26, 2016
Dec-24-16 06:09PM  GlaxoSmithKline, Vodafone Hit 3-Year Low Prices
Dec-21-16 01:27PM  GlaxoSmithKline PLC (ADR) (GSK) Phase 3 Trials Looks Positive: Will Gilead Sciences, Inc. (GILD) Endure? at Insider Monkey
Dec-20-16 11:25AM  Gilead Sciences: How Bad is the Glaxo News? at Barrons.com
09:28AM  GSK launches big study to test new injection for HIV prevention
03:31AM  GSK's two-drug HIV therapy shines in two big studies Reuters
Dec-19-16 08:30AM  Merck Keytruda Gets CHMP Nod for First-Line Lung Cancer
08:26AM  Pfizer Chantix Label Warning Lifted in U.S.; to Add New Data
04:30AM  GSK Starts Phase III Study of Once-Daily Closed Triple Combination Therapy FF/UMEC/VI in Patients with Asthma Business Wire
Dec-16-16 04:56PM  US drops bold warning from anti-smoking pills Chantix, Zyban
03:28PM  [$$] FDA Drops Stringent Warning on Smoking-Cessation Drug Chantix at The Wall Street Journal
Dec-15-16 04:22PM  Big Pharma Face Off: Is Merck More Attractive than J&J?
Dec-13-16 02:12PM  How You Can Profit as the Market for COPD Drugs Grows
02:10PM  GSK's Witty: We need to get drug pricing right
Dec-12-16 12:46PM  With Obamacare repealed, 1 in 4 adults could be uninsurable due to a pre-existing condition at MarketWatch
Dec-11-16 01:00PM  How drugs like Tylenol and Flonase are saving the US $102 billion
Dec-09-16 09:16PM  A new Lyme disease vaccine will soon be tested on Americans and Europeans
Dec-07-16 11:47AM  Asset Sales, New Projects Fuel 6.7% Yield
09:21AM  Pfizer Takes $106 Million Fine From U.K. for Price Hike of Epilepsy Drug
Dec-06-16 07:02AM  Has GlaxoSmithKline Finally Turned the Corner? at Motley Fool
Dec-05-16 10:33AM  Robust Pipeline Supports 5.5% Dividend Yield
09:36AM  GSK insider Waterhouse to head drugmaker's HIV unit ViiV
07:30AM  Adaptimmune Announces Initiation of Myxoid/Round Cell Liposarcoma Study GlobeNewswire
Dec-04-16 05:08PM  What Smart Money Thinks About GlaxoSmithKline plc (ADR) (GSK) at Insider Monkey
Dec-02-16 02:59PM  How to Buy GlaxoSmithKline at a 15% Discount
01:26PM  GlaxoSmithKline PLC (ADR) (GSK) Wins Approval Of Its Asthma Drug Nucala at Insider Monkey
11:27AM  Glaxo and Innoviva Get Positive News (GSK, INVA) at Investopedia
11:23AM  How China Makes Money (BABA, PFE) at Investopedia
09:15AM  GSK Files Regulatory Submission in European Union for Once-Daily Closed Triple Combination Therapy FF/UMEC/VI for Patients with COPD Business Wire
02:00AM  Relvar® Ellipta® 100/25 mcg Gains Approval in Japan for Use in Patients with COPD Business Wire
Dec-01-16 04:48PM  Here's the Best Dividend Stock in Big Pharma at Motley Fool
08:04AM  AbbVie Is Focused on Growth Opportunities in Neuroscience Space
Nov-30-16 12:56PM  GlaxoSmithKline PLC (ADR) (GSK) Targeting Blockbuster Sales With Shingles Vaccine On EU Approval at Insider Monkey
Nov-29-16 04:00PM  GlaxoSmithKline Plans Nigeria Health Boost After Drinks Sale at Bloomberg
10:35AM  Should You Buy 3M Co (MMM)? at Insider Monkey
09:17AM  Injections, implants tested as new weapons to prevent HIV
07:00AM  [$$] Pharma giants see future of lower healthcare profits at Financial Times
07:00AM  [$$] Big data promise exponential change in healthcare at Financial Times
Nov-28-16 08:29AM  Glaxo (GSK) Files Regulatory Application for Shingrix in EU
Nov-25-16 11:33AM  GlaxoSmithKline Studies EPO-Like Anemia Drug (GSK) at Investopedia
Nov-24-16 08:11AM  Glaxo Nucala Favorable in Rare Vasculitis Disease Study
07:13AM  GSK chases Astra with start of big anaemia drug trials Reuters
Nov-23-16 11:20AM  Smart Money Continues to Lose Confidence In McDonalds Corporation (MCD) at Insider Monkey
08:41AM  5 Very Safe Dividend Stocks to Buy Now and Hold Forever at 24/7 Wall St.
Nov-22-16 06:30PM  6 Worthy Dividend Stocks Down 10% or More
03:56PM  GlaxoSmithKline Seeks FDA OK for COPD Inhaler (GSK) at Investopedia
09:49AM  Heres Our Take On Theravance Biopharma Inc (TBPH) And GlaxoSmithKline PLC (ADR) (GSK)s Latest Submission at Insider Monkey
09:00AM  Glaxo Files for COPD Drug; FluLaval Approved for Infants
08:15AM  Blog Coverage GlaxoSmithKline Files for US Approval for Triple Combination Lung Cancer Therapy Accesswire
Nov-21-16 05:04PM  Copaxone May Face Competitive Pressures in the Future
02:04PM  2 Excellent Dividend-Paying Drug Stocks to Add to Your Portfolio
11:15AM  GSK seeking FDA approval for 'triple combination' COPD therapy at bizjournals.com
08:28AM  GSK receives FDA approval for expanded indication for FluLaval® Quadrivalent (Influenza Vaccine) for infants 6 months and older PR Newswire
07:00AM  GSK files regulatory submission in US for once-daily closed triple combination therapy FF/UMEC/VI for patients with COPD PR Newswire
03:00AM  GlaxoSmithKline seeks U.S. approval for triple lung drug Reuters
02:00AM  GSK Files Regulatory Submission in US for Once-Daily Closed Triple Combination Therapy FF/UMEC/VI for Patients with COPD Business Wire
Nov-18-16 10:04AM  Innovative Research in Vaccines May Boost Pfizers Revenues
08:16AM  Better Buy: AbbVie Inc. vs. GlaxoSmithKline PLC at Motley Fool
Nov-17-16 10:51PM  Glaxo (GSK) Presents Phase III Data on Sirukumab & Benlysta
11:04AM  How Sandoz Performed for Novartis in 3Q16
Nov-16-16 05:04PM  Novartiss 3Q16 Earnings Surpass Analyst Estimates
11:31AM  Ex-sleuths sue GlaxoSmithKline over imprisonment in China
Nov-15-16 10:50AM  Sanofi, GSK expect further price pressure, more M&A under Trump Reuters
Nov-14-16 11:02AM  New Phase IV Data On VBI Vaccines, Inc. (VBIV) HBV Vaccine Show It Can Carve Out A Market From GlaxoSmithKline PLC (ADR) (GSK) at Insider Monkey
GlaxoSmithKline plc creates, discovers, develops, manufactures, and markets pharmaceutical products, including vaccines, over-the-counter medicines, and health-related consumer products worldwide. The company operates through five segments: Global Pharmaceuticals, HIV, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. It offers pharmaceutical products in the therapeutic areas, including respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, and emesis, dermatology, rare diseases, immuno-inflammation, vaccines, and HIV. The company also provides consumer healthcare products in wellness, oral health, nutrition, and skin health areas under the Sensodyne, Horlicks, Parodontax, Poligrip, Voltaren, Panadol, Otrivin, Tums, Flonase, Eno, and Theraflu brand names. GlaxoSmithKline plc offers its consumer healthcare products in the form of tablets, caplets, infant syrup drops, topical gels, nasal sprays, effervescents, lozenges, gum and trans-dermal patches, malted drinks and foods, and creams. The company has a strategic collaboration with Miltenyi Biotec GmbH to develop a cell and gene therapy automation and processing technology; and a partnership with Fimbrion Therapeutics for the development of a small molecule drug to treat prevent urinary tract infections. GlaxoSmithKline plc was founded in 1935 and is headquartered in Brentford, the United Kingdom.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
GLAXOSMITHKLINE PLC10% OwnerOct 24Buy14.0066,500931,0003,220,627Oct 26 05:49 PM